1. You Don't Know JAK in IBD

2. Epidemiology of IBD

3. Burden of Disease

4. Factors Contributing to Pathogenesis of IBD

5. CD and UC Are Progressive

6. CD and UC Are Progressive (cont)

7. Immunopathogenesis of IBD

8. Goals of IBD Therapy

9. Treat to Target

10. FDA-Approved Therapies for IBD

11. Limitations of Current IBD Treatments

12. New and Emerging Treatments in IBD

13. Tofacitinib

14. Tofacitinib in Adults With UC OCTAVE 1 and 2 Studies

15. Tofacitinib in CD

16. Investigational JAK Inhibitors in IBD

17. Filgotinib in Moderate to Severe CD FITZROY Study Results

18. Upadacitinib in Moderate to Severe CD Celest Study Results

19. IL-12/-23 Antagonists

20. Selective Adhesion Molecule Inhibitors

21. S1P Receptor Modulators

22. S1P Receptor Modulators (cont)

23. Other Emerging Therapies in IBD

24. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)